Translation: Original published in Finnish on 7/6/2026 at 9:04 am EEST.

Nexstim announced on Friday that it had received an order for an NBS 6 system from a new customer in the United States. The system is used for therapy applications, such as the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The news is a positive continuation of the larger device order announced in June and supports our growth forecasts.

The US is a key market for Nexstim in the therapy business, and winning a new customer supports the company's growth strategy. We expect the company's full-year 2026 revenue to grow by just under 16% to 12.7 MEUR, which necessitates a steady flow of equipment orders throughout the year.